Ventyx Biosciences logo
Ventyx Biosciences
VTYX | NASDAQ
Chart Builder DCF Calculator
$14.00
$0.00 (0.00%)
At close: Mar 3, 2026, 4:00 PM ET

Ventyx Biosciences Company Profile

Company profile explained

Company Profile

Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.

Key Executives

Name Position
Raju S. Mohan Founder, Chief Executive Officer, President & Director
Matthew Richard Moore Chief Operating Officer
Arline Nakanishi Senior Vice President of Biometrics
John Nuss Chief Scientific Officer
Kathy Ogilvie Senior Vice President of Translational & Nonclinical Research
Mark S. Forman Chief Medical Officer
Roy Gonzales Senior Vice President of Finance and Principal Financial & Accounting Officer
Sheila K. Gujrathi Executive Chairperson
Snehal Naik Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
May 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
May 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Mar 16, 2026 15-12G Filing
Mar 06, 2026 EFFECT Filing
Mar 06, 2026 EFFECT Filing
Mar 05, 2026 SC 13D/A [Amend] Filing
Mar 04, 2026 4 Filing
Mar 04, 2026 4 Filing
Mar 04, 2026 4 Filing
View All SEC Filings ➞
Ventyx Biosciences
Ventyx Biosciences logo
Country United States
IPO Date Oct 21, 2021
Industry Biotechnology
Sector Healthcare
Employees 81
CEO Sheila K. Gujrathi

Contact Details

662 Encinitas Boulevard San Diego, California 92024 United States

Stock Details

Ticker Symbol VTYX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001851194
CUSIP Number 92332V107
ISIN Number US92332V1070
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.